Akèy › Ateroskleroz › North Carolina
Etid klinik pou Ateroskleroz nan North Carolina
12 etid pou Ateroskleroz ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- UNC Heart & Vascular, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07448038Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Care Access - Fayetteville, Fayetteville
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07157774Study of the Effect of Innate on the Inflammatory Response to Endotoxin
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Sep 22, 2026 · NCT01143480Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Novant Health Heart and Vascular Institute, Charlotte
- Velocity Clinical Research - Durham, Durham
- Moses H Cone Memorial Hospital, Greensboro
- ak 7 plis
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- NC Heart and Vascular Research, LLC, Raleigh
- Javara Inc. - Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07521007Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Metrolina Nephrology Associates, PA, Charlotte
- Durham Nephrology Associates, PA, Durham
- Duke Translational Medicine Institute, Durham
- ak 3 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Asheville
- Research Site, Chapel Hill
- Research Site, Charlotte
- ak 11 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Wake Forest University Baptist Medical Center, Winston-Salem
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Aug 7, 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Monroe Biomedical Research, Monroe
- Alliance Medical Ministry, Raleigh
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Jul 29, 2026 · NCT06875973Pharmacogenomic Informed Statin Prescribing
- Durham VA Medical Center, Durham, NC, Durham
Ap rekrite
Laj 40 a 75 · Tout sèks · Mizajou Apr 13, 2026 · NCT06568601Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 2
Laj 40 a 75 · Tout sèks · Mizajou Feb 27, 2026 · NCT06488105Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Durham VA Medical Center, Durham, NC, Durham
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT02915198Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.